Thank you.
My next question has to do with something you say in First Do No Harm: Responding to Canada’s Prescription Drug Crisis. You state, in your second paragraph, “Develop and promote risk-reduction programs for individuals...”. Can you elaborate on that? As you said, the lead is Health Canada, the Public Health Agency of Canada. So perhaps you can elaborate on it.
I also want to thank you for your last answer, because I think all of us who have been involved in looking at this issue know that if you're going to set up, you're going to evaluate, you're going to monitor, and you're going to look at indicators, then you're going to need data first. You're going to need data that has been broken down by particular groups and demographics, and other data that tells us who's more prone, etc.
Thanks, Mr. Perron.